Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis
- 22 June 1992
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 92 (6), S86-S94
- https://doi.org/10.1016/0002-9343(92)90614-h
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Advances in the understanding and treatmentof urinary tract infections in young womenUrology, 1991
- Treatment of pyelonephritis in an observation unitAnnals of Emergency Medicine, 1991
- Management of acute pyelonephritis in an emergency department observation unitAnnals of Emergency Medicine, 1991
- Pyelonephritis in adult women: inpatient versus outpatient therapyThe American Journal of Medicine, 1988
- Comparative in-vitro activity of a new oral carbacephem, LV163892Journal of Antimicrobial Chemotherapy, 1988
- Antimicrobial activity of LY163892, an orally administered 1-carbacephemJournal of Antimicrobial Chemotherapy, 1988
- In vitro activity and beta-lactamase stability of LY163892European Journal of Clinical Microbiology & Infectious Diseases, 1988
- In-vitro activity and β-lactamase stability of LY163892Journal of Antimicrobial Chemotherapy, 1988
- In vitro activities of LY163892, cefaclor, and cefuroximeAntimicrobial Agents and Chemotherapy, 1988
- Acute Renal Infection in Women: Treatment with Trimethoprim-Sulfamethoxazole or Ampicillin for Two or Six WeeksAnnals of Internal Medicine, 1987